Spoken Alpha
AUPH
Aurinia Pharmaceuticals Inc.
Overview
Aurinia Pharmaceuticals Inc is a Healthcare company operating in Biotechnology with a $2.44B market cap.
Most recent reported earnings: Q2 FY2026 (Jul 29, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2025Earnings2026-02-2613 Q&A exchanges
- Q3 FY2025Earnings2025-11-0412 Q&A exchanges
- Q2 FY2025Earnings2025-07-319 Q&A exchanges
- Q1 FY2025Earnings2025-05-1217 Q&A exchanges
- Q4 FY2024Earnings2025-02-278 Q&A exchanges
- Q3 FY2024Earnings2024-11-076 Q&A exchanges
- Q2 FY2024Earnings2024-08-0112 Q&A exchanges
- Q1 FY2024Earnings2024-05-0212 Q&A exchanges
- Q4 FY2023Earnings2024-02-1512 Q&A exchanges
- Q3 FY2023Earnings2023-11-0227 Q&A exchanges
- Q2 FY2023Earnings2023-08-0321 Q&A exchanges
- Q1 FY2023Earnings2023-05-0420 Q&A exchanges
- Q4 FY2022Earnings2023-02-2817 Q&A exchanges
- Q3 FY2022Earnings2022-11-0329 Q&A exchanges
- Q2 FY2022Earnings2022-08-0418 Q&A exchanges
- Q1 FY2022Earnings2022-05-1032 Q&A exchanges
- Q4 FY2021Earnings2022-02-2818 Q&A exchanges
- Q3 FY2021Earnings2021-11-0328 Q&A exchanges
- Q2 FY2021Earnings2021-08-0517 Q&A exchanges
- Q1 FY2021Earnings2021-05-0724 Q&A exchanges
History
Earnings history
- Q2 FY20262026-07-29EPS— vs $0.25—Rev— vs ——EODHD
- Q1 FY20262026-04-29EPS$0.25 vs $0.16+56.3%Rev$77.7M vs ——EODHD
- Q4 FY20252026-03-03EPS$1.53 vs $0.15+100.0%Rev$77.1M vs ——EODHD
- Q3 FY20252025-11-03EPS$0.23 vs $0.16+43.8%Rev$73.5M vs ——EODHD
- Q2 FY20252025-07-30EPS$0.16 vs $0.14+14.3%Rev$70.0M vs ——EODHD
- Q1 FY20252025-04-29EPS$0.16 vs $0.10+60.0%Rev$62.5M vs ——EODHD
- Q4 FY20242025-02-12EPS$0.01 vs $-0.02+100.0%Rev$59.9M vs ——EODHD
- Q3 FY20242024-11-06EPS$0.10 vs $0.01+100.0%Rev$67.8M vs ——EODHD
- Q2 FY20242024-07-31EPS$0.01 vs $0.010.0%Rev$57.2M vs ——EODHD
- Q1 FY20242024-05-01EPS$-0.03 vs $-0.14+78.6%Rev$50.3M vs ——EODHD
- Q4 FY20232024-02-14EPS$-0.19 vs $-0.16-18.8%Rev$45.1M vs ——EODHD
- Q3 FY20232023-11-01EPS$-0.09 vs $-0.17+47.1%Rev$54.5M vs ——EODHD
- Q2 FY20232023-08-02EPS$-0.08 vs $-0.18+55.6%Rev$41.5M vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.18 vs $-0.22+18.2%Rev$34.4M vs ——EODHD
- Q4 FY20222023-02-27EPS$-0.18 vs $-0.27+33.3%Rev$28.4M vs ——EODHD
- Q3 FY20222022-11-02EPS$-0.06 vs $-0.17+64.7%Rev$55.8M vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.25 vs $-0.22-13.6%Rev$28.2M vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.27 vs $-0.270.0%Rev$21.6M vs ——EODHD
- Q4 FY20212022-02-27EPS$-0.25 vs $-0.27+7.4%Rev$23.4M vs ——EODHD
- Q3 FY20212021-11-02EPS$-0.39 vs $-0.33-18.2%Rev$14.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-07-29 | — | $0.25 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-04-29 | $0.25 | $0.16 | +56.3% | $77.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-03 | $1.53 | $0.15 | +100.0% | $77.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $0.23 | $0.16 | +43.8% | $73.5M | — | — | EODHD |
| Q2 FY2025 | 2025-07-30 | $0.16 | $0.14 | +14.3% | $70.0M | — | — | EODHD |
| Q1 FY2025 | 2025-04-29 | $0.16 | $0.10 | +60.0% | $62.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-12 | $0.01 | $-0.02 | +100.0% | $59.9M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $0.10 | $0.01 | +100.0% | $67.8M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $0.01 | $0.01 | 0.0% | $57.2M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.03 | $-0.14 | +78.6% | $50.3M | — | — | EODHD |
| Q4 FY2023 | 2024-02-14 | $-0.19 | $-0.16 | -18.8% | $45.1M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.09 | $-0.17 | +47.1% | $54.5M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.08 | $-0.18 | +55.6% | $41.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.18 | $-0.22 | +18.2% | $34.4M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $-0.18 | $-0.27 | +33.3% | $28.4M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.06 | $-0.17 | +64.7% | $55.8M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.25 | $-0.22 | -13.6% | $28.2M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.27 | $-0.27 | 0.0% | $21.6M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.25 | $-0.27 | +7.4% | $23.4M | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $-0.39 | $-0.33 | -18.2% | $14.7M | — | — | EODHD |
Source: EODHD. AUPH reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks AUPH's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $2.81 | $3.53 | -20.4% | -2.0% | -4.8% |
| Q4 FY2025 | $2.46 | $3.42 | -28.2% | +4.3% | +1.5% |
| Q3 FY2025 | $2.34 | $3.40 | -31.2% | +5.5% | +6.1% |
| Q2 FY2025 | $2.94 | $3.58 | -17.8% | -0.3% | -2.2% |
| Q1 FY2024 | $2.67 | $3.37 | -20.9% | +2.6% | +4.0% |
| Q4 FY2024 | $2.88 | $3.65 | -21.2% | -2.3% | -4.2% |
| Q3 FY2024 | $2.70 | $3.42 | -21.0% | +2.3% | +3.3% |
| Q2 FY2024 | $2.89 | $3.58 | -19.2% | -0.3% | +0.1% |
| Q1 FY2023 | $2.40 | $3.49 | -31.2% | +2.5% | +1.4% |
| Q4 FY2023 | $2.74 | $3.48 | -21.4% | +6.3% | +6.6% |
Guidance change history
Sample- Q1 FY2025Lowered2025-04-15
- Q4 FY2025Lowered2025-13-15
- Q3 FY2025Lowered2025-10-15
- Q2 FY2025Lowered2025-07-15
- Q1 FY2024Lowered2024-04-15
- Q4 FY2024Lowered2024-13-15
- Q3 FY2024Lowered2024-10-15
- Q2 FY2024Lowered2024-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Peter GreenleafCEO1 yr 4 mo20 callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • last guidance raise Q3 FY2025
- Michael S HearneCFO3 mono recorded callsCurrentSample
CFO since 2026 • 1/2 beats (50%) • last call held guidance Q2 FY2025
- Joseph M MillerCFO1 yr 4 mo20 callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2025
- Ryan ColeCOO3 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • last guidance raise Q1 FY2025
- Matthew Maxwell DonleyCOO1 yr 4 mono recorded callsCurrentSample
COO since 2025 • 1/2 beats (50%) • last call held guidance Q1 FY2025
- Greg KeenanSVP, Chief Medical Officer4 mo8 callsCurrentSample
OTHER_C_SUITE since 2026 • 1/2 beats (50%) • last guidance raise Q3 FY2025
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AUPH.
$ curl https://api.spokenalpha.com/v1/companies/AUPHFAQ
Frequently asked about AUPH
Where can I find Aurinia Pharmaceuticals Inc.'s (AUPH) earnings call transcripts?
Spoken Alpha indexes AUPH's earnings call transcripts at https://spokenalpha.com/companies/AUPH. Each call links to attributed speakers and parsed analyst Q&A. Aurinia Pharmaceuticals Inc.'s own investor relations page is at https://www.auriniapharma.com/investors.
When was Aurinia Pharmaceuticals Inc.'s most recent earnings call?
Aurinia Pharmaceuticals Inc. (AUPH) held its most recent earnings call on 2026-02-26, covering fiscal Q4 2025.
What sector is AUPH in?
Aurinia Pharmaceuticals Inc. (AUPH) operates in the Healthcare sector (Biotechnology industry).